Erkang Pharmaceutical (300267): Plant starch, a breakthrough in the field of pharmaceutical supplements, ushered in the harvest period
Comments on Erkang Pharmaceutical (300267) Annual report and Quarterly report: modified starch drives sustained High growth Pharmaceutical Industry Integration
Erkang Pharmaceutical (300267) Annual report comments: performance in line with expectations starch series products drive high growth
Comments on Erkang Pharmaceutical (300267) Annual report: benefiting from the change of Drug Review Policy, the main business grows rapidly
[Soochow Securities] Erkang Pharmaceutical: starch capsule products are growing at a high speed, and the policy dividend helps the company's long-term development.
[Haitong] Erkang Pharmaceutical Company announced comments: the inspection results finally landed and continued to maintain high growth.
Erkang Pharmaceutical (300267) Quarterly report comments: starch capsule product rapid growth policy dividend helps the company's long-term development
Erkang Pharmaceutical (300267) Quarterly report comments: profits maintain rapid growth starch capsules enter the market before the year
Erkang Pharmaceutical (300267): the inspection results finally continue to maintain high growth.
Erkang Pharmaceutical (300267) Quarterly report comments: the performance is in line with the expected high-speed growth policy of modified starch.
尔康制药(300267)半年报点评:业绩超预期 政策长期利好
尔康制药(300267)中报点评:淀粉系列产品、磺苄均实现高增长
【国信证券】尔康制药2016年中报点评:淀粉胶囊系列持续高速增长,下游制剂拓展是未来看点
尔康制药(300267)中报点评:淀粉胶囊系列持续高速增长 下游制剂拓展是未来看点
尔康制药(300267):淀粉软胶囊原料、小品种辅料快速放量 业绩大幅超出市场预期
尔康制药(300267):警方查获亿粒毒胶囊 淀粉胶囊大势所趋
【海通证券】尔康制药公司信息点评:警方查获亿粒毒胶囊,淀粉胶囊大势所趋
尔康制药(300267):签订海外大单 打开巨大成长空间
【海通证券】尔康制药公司公告点评:签订海外大单,打开巨大成长空间
尔康制药(300267):政策巨震催生尔康制药投资新逻辑
No Data
No Data